Skip to content
  • COMPANY
    • OVERVIEW
    • LEADERSHIP
    • BOARD
    • TIMELINE
  • OUR NETWORK
    • FOUNDERS
    • CONSULTANTS
    • INVESTORS
  • OUR SCIENCE
    • INTRODUCTION
    • Mode of Action
    • SCIENCE LIBRARY
  • PIPELINE
    • OVERVIEW
    • PMD-OPTION study
    • OMT-28
  • NEWS & EVENTS
  • TEAM & CAREERS
  • LEGAL NOTICE
  • DISCLAIMER
  • DATA PROTECTION

Nothing Found

Sorry, but nothing matched your search terms. Please try again with some different keywords.

Recent Posts

  • OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
  • Scientific Library 1
  • Scientific Library 2
  • Scientific Library 3
  • OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease

Recent Comments

    Archives

    • September 2024
    • August 2024
    • September 2023
    • June 2023
    • March 2023
    • December 2022
    • September 2019
    • April 2019
    • March 2019
    • February 2019
    • November 2018
    • July 2018
    • April 2018
    • November 2017
    • October 2017
    • June 2017
    • March 2017
    • November 2015
    • April 2015

    Categories

    • AdvisoryBoard
    • Board
    • Consultants
    • development
    • EVENTS
    • financing
    • Founders
    • Management
    • meeting
    • NEWS
    • Partner
    • SCIENCE LIBRARY
    • staff

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    OMEICOS Therapeutics GmbH
    Robert-RΓΆssle-Strasse 10 (Building 79)
    13125 Berlin, Germany
    t +49 (0)30 9489 4810
    f +49 (0)30 9489 4811
    info@omeicos.com
    OMEICOS Therapeutics, Inc.
    c/o Remiges Biopharma Fund GP, Inc.
    One Broadway, 14th Floor,
    Cambridge, MA 02142, USA
    info@omeicos.com
    • LEGAL NOTICE
    • DISCLAIMER
    • DATA PROTECTION
    FOLLOW US
    © 2025 OMEICOS THERAPEUTICS GMBH. ALL RIGHTS RESERVED.